Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Other Accumulated Expenses (2021 - 2023)

Werewolf Therapeutics (HOWL) has disclosed Other Accumulated Expenses for 3 consecutive years, with $1.6 million as the latest value for Q2 2023.

  • On a quarterly basis, Other Accumulated Expenses fell 86.39% to $1.6 million in Q2 2023 year-over-year; TTM through Jun 2023 was $1.6 million, a 86.39% decrease, with the full-year FY2022 number at $6.5 million, changed N/A from a year prior.
  • Other Accumulated Expenses was $1.6 million for Q2 2023 at Werewolf Therapeutics, down from $4.1 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $11.8 million in Q2 2022 to a low of $20000.0 in Q1 2021.
  • A 3-year average of $5.8 million and a median of $5.3 million in 2022 define the central range for Other Accumulated Expenses.
  • Biggest YoY gain for Other Accumulated Expenses was 86.39% in 2023; the steepest drop was 86.39% in 2023.
  • Werewolf Therapeutics' Other Accumulated Expenses stood at $20000.0 in 2021, then surged by 32560.0% to $6.5 million in 2022, then tumbled by 75.41% to $1.6 million in 2023.
  • Per Business Quant, the three most recent readings for HOWL's Other Accumulated Expenses are $1.6 million (Q2 2023), $4.1 million (Q1 2023), and $6.5 million (Q4 2022).